ACOTEC
先瑞达

Acotec Scientific Holdings Limited

2025FY Business Performance Review

Mar. 2026

TRUSTED INNOVATION
FOR LIFE

ACOTEC
先瑞达

Legal Disclaimer

- This Presentation is strictly confidential and subject to the terms and conditions described below. It is only sent to some people and provided with information about Acotec Scientific Holdings Limited (the "Company") to help you decide whether to conduct in-depth research on the Company. The information contained in this Presentation has not been verified by any regulatory agency in any jurisdiction. The content of this Presentation (regardless of all or part of the content and regardless of the purpose) shall not be copied, distributed or shared directly or indirectly with any person (regardless of whether such person is a member of your company or group). In particular, neither the information contained in this Presentation nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in the United States, Canada, Australia, Japan, Hong Kong, Singapore or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of U.S. or other national securities laws. Anyone who obtains this Presentation should understand or be familiar with such restrictions.
- This Presentation and the information contained therein have not been independently verified and are not intended to constitute the basis for making investment decisions. The content of this Presentation does not constitute or form and shall not be construed as a solicitation of an offer for the sale or purchase of securities under any other jurisdiction. Any part of this Presentation does not constitute the basis of any contract or undertaking. Any decision to purchase the Company's securities in a public or private offering shall be based on the prospectus or international offering circular prepared by the Company for the relevant securities offering and any supplementary price information. This Presentation does not include any information or materials that would cause this Presentation to constitute(i) a prospectus under Section 2(1) of the Companies (Winding Up and Miscellaneous Provisions) (Cap.32 of Hong Kong) or the Securities Act of 1933 (as amended) (the “Securities Act"), or an advertisement in relation to a prospectus or proposed prospectus, or an extract from or abridged version of a prospectus under Section 38B of the Companies (Winding-up and Miscellaneous Provisions), or an advertisement, invitation or document which contains any advertisement or invitation under Section 103 of the Securities and Futures Ordinance (Cap. 571 of Hong Kong), or (ii) an invitation to the public made in Hong Kong without abiding by Hong Kong law or introducing exemptions under Hong Kong law. This Presentation is subject to change without notice.
- The Company’s securities have not been and will not be registered under the Securities Act or the securities law of any state in the United States, and may not be offered or sold in the United States without registration or obtaining relevant applicable exemptions. Neither this Presentation nor its content constitutes or forms, and shall not be construed as part of an offer or solicitation of an offer to subscribe for securities in the United States. The Presentation shall not be carried or transmitted to the United States (including its territories and commonwealths, any state or the District of Columbia), or distributed directly or indirectly in the United States (including its territories and commonwealths, any state or District of Columbia). The Company's securities will not be offered or sold in the United States except for transactions that are not subject to exemptions under the provisions of the Securities Act or not subject to the Securities Act.
- By participating in or by reading this Presentation, you are recognized to have made representations and warranties to the Company, the parties involved in the Company’s securities issuance, or their respective affiliates, controllers, directors, managers, partners, employees, agents, representatives or advisors that you and any you represent (if any) are either (i) a “qualified institutional buyer” (within the meaning of Rule 144A under the United States Securities Act of 1933, as amended), or (ii) outside the United States.. You are also deemed to have represented and agreed that you and any customers you represent are professional investors as defined in the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and any rules made thereunder.
- The information in this Presentation is provided by the Company. This Presentation is not intended to be comprehensive or to contain all the information you may need to evaluate the Company. Regarding the accuracy, reliability, correctness, reasonableness, fairness or completeness of this Presentation or any information therein, or any oral or written communication regarding the evaluation of the Company, none of the parties (to avoid ambiguity, including but not limited to the Company, the parties involved in the Company’s securities issuance, or their respective affiliates, controllers, directors, managers, partners, employees, agents, representatives or advisors) has or will make any express or implied statement or guarantee, and shall not, within the scope permitted by law, assume any liability arising therefrom. In particular, regarding the realization or reasonableness of any assumptions, speculations, goals, estimates or prospects contained in this Presentation, no express or implied statements or guarantees are made, nor should you rely thereon. Some of the information contained herein comes from different sources, including some third parties, and has not been independently verified by the Company. For the losses caused to you or any person using or relying on the information contained or disclosed in this Presentation, the Company, the parties involved in the Company’s securities issuance, or their respective affiliates, controllers, directors, managers, partners, employees, agents or representatives shall take no responsibility (whether in negligence or otherwise). The use of registered trademarks, commercial trademarks and logos or photographic materials within this Presentation are exclusively for illustrative purposes and are not meant to violate the rights of the creators and/or applicable intellectual property laws.
- This Presentation is subject to the disclaimer and restrictive language contained therein. Any person shall make their independent evaluation and analysis, and shall not use any information mentioned, discussed or quoted in therein as the basis for their actions. You understand and assure the Company, the parties involved in the Company’s securities issuance, or their respective affiliates, controllers, directors, managers, partners, employees, agents, representatives or advisors that you are a professional investor and have the knowledge, experience and ability required to evaluate the Company, you will make independent evaluation of the Company, its securities and all the information provided, and you have or will obtain independent advice for the evaluation of the Company’s securities.
- This Presentation may contain the Company’s current beliefs and expectations regarding the indicated future dates. Such forward-looking statements are based on some assumptions about the Company’s operations or factors outside the Company’s control, and may be affected by a number of known and unknown factors. Therefore, the Company’s actual performance may be materially different from these forward-looking statements. You shall not rely on such forward-looking statements. The Company, the parties involved in the issuance of the Company’s securities, or their respective affiliates, controllers, directors, managers, partners, employees, agents, representatives or advisors shall not be obliged to update or revise such forward-looking statements in response to new information, events or circumstances that occur after these dates.
- This Presentation and the information contained therein are strictly confidential. This Presentation and the information contained therein shall not be copied, reproduced, or transmitted to others in any form, or disclosed for any purpose (whether in whole or in part). Failure to comply with these restrictions may constitute a violation of the law and may result in legal or regulatory action. By receiving this Presentation or the information therein, you agree (1) that you have read and agree to abide by the requirements in this disclaimer; and (2) that you will keep the information contained in this Presentation strictly confidential.
- By participating in and accepting this Presentation, you agree to maintain the absolute confidentiality of the information contained in this Presentation and accept the restrictions and other conditions stated therein. Failure to comply with these restrictions and conditions may violate relevant laws and regulations and result in legal or regulatory measures.

ACOTEC
先瑞达

01 2025FY Financial Performance Review

02 The Progress of CCT Implementation

03 Product Commercialization

04 R&D, Product Approvals, and Manufacturing Status

05 Q&A

TRUSTED INNOVATION
FOR LIFE

AGOTEC
先瑞达

TRUSTED INNOVATION
FOR LIFE

01

2025FY Financial Performance Review

2025FY Financial Performance Review (1/3)

TRUSTED INNOVATION
FOR LIFE

Revenue

(In millions RMB)



- In 2025, the Company's business grew steadily, achieving a total revenue of **RMB 645 mn**, a yoy increase of **20.7%**.
- Benefiting from a steady stream of product launches, the Company achieved a diversified revenue structure. Peripheral DCB products generated RMB 319 mn, while **venous intervention, vascular access and other businesses reached RMB 326 mn (+52.4% yoy), accounting for 51% of total revenue**. Driven by the increasing penetration of venous products and the commercialization of new products, this segment recorded strong growth and has become an important driver of the Company's business dynamics.

Gross Profit & Gross Profit Margin

(In millions RMB)



- In 2025, the Company recorded **a gross profit of RMB 476 mn**, with a **gross margin of 74%**, remaining at an industry-leading level and basically flat compared to 2024.
- Key Drivers for top-tier gross margin: 1) Continuous optimization of gross margin for venous and access products after volume ramp-up; 2) DCB products, with over a decade of commercialization, have maintained a good gross margin level; 3) Implementation of cost-reduction and efficiency-improvement measures, including replacing purchased raw materials with in-house produced ones and optimizing production processes.

2025FY Financial Performance Review (2/3)

TRUSTED INNOVATION
FOR LIFE

R&D expenses



- In 2025, R&D expenses amounted to approximately **RMB 214 mn**, reflecting a slight decrease of 1.4% yoy. The company remains focused on tracking clinical and market needs, initiating new projects, and advancing key R&D and registration activities globally, thereby strengthening the foundation for future growth.
- The **R&D expense ratio fell to about 33%, compared to 41% in 2024**, largely driven by strong revenue expansion and increasing benefits from platform synergies.

Selling and distribution expenses



- Sales and distribution expenses in 2025 reached approximately **RMB 105 mn**, rising 13.7% yoy. This increase was primarily due to **expanded market outreach and academic activities following several new product launches**, which were aimed at enhancing physician and patient education, elevating brand presence, and boosting product recognition to sustain competitive advantage.
- The **sales expense ratio declined to 16%,** primarily benefiting from reasonable activity planning and refined operational management.

Administrative expenses



- 2025 saw further benefits from the company's ongoing operational streamlining. Administrative expenses totaled **RMB 77 mn**, accounting for 12% of revenue—**maintaining an efficient and stable level.**

2025 Financial Performance Review (3/3)

TRUSTED INNOVATION
FOR LIFE

Net Profit & Adjusted Net Profit

(In millions RMB)



- In 2025, the Company achieved **a net profit** of **RMB 119.2 mn**, representing a yoy increase of 128%
- Excluding approximately RMB 12.2 mn in exchange losses and around RMB 9.3 mn in share-based payment, the company delivered **an adjusted net profit** of approximately **RMB 141 mn**, up 168% yoy.
- With the launch of more products, the Company demonstrated strong business growth and an increasingly diversified revenue structure. Effective cost optimization and precision management measures further contributed to accelerated profitability.

Liquidity and Financial Resources

- As of the end of 2025, the Company's available financial resources totaled approximately **RMB 950 million**.
- Sufficient cash reserves ensure stable operations and support business development opportunities.

02

The Progress of CCT Implementation

Synergy for Success，A New Chapter Begins: Acotec & BSC Sign 2026 Framework Agreement to Deepen Strategic Partnership

TRUSTED INNOVATION
FOR LIFE

Phase 1

2023-2025
Foundation & Capability Building

Leveraged the 2023 Framework Agreement to establish aligned pathways in commercialization, R&D, and manufacturing, and validated core capabilities.

Phase 2

2026-2028
Acceleration & Momentum Scaling

Building on the 2026 Framework Agreement to advance our collaboration from a "preparation phase" to a phase of "accelerated delivery."

Product Commercialization

- Strengthening global RA capabilities and quality systems to drive compliance and align supply chain responsiveness with market demands.

Bringing Chinese innovation to patients worldwide

Joint R&D

- Combining BSC's global vision with Acotec's local execution to precisely target high-potential products.

Co-developing a more competitive product portfolio

Manufacturing Services

- Establishing a strong foundation in cost-efficiency, responsiveness, and scalable production.

Validating Acotec's manufacturing capability

Key Updates on Collaboration with BSC: Product Commercialization

TRUSTED INNOVATION
FOR LIFE

Global Expansion Landscape of Collaborative Products

Global Footprint

SFA DCB
AcoArt Orchid®

BTK DCB
AcoArt Tulip® & Litos®

- As of today, AcoArt DCBs have been launched in 17 countries outside of China.
- Acotec will continue to advance global registrations aligned with BSC's distribution plan, bringing DCB products to more markets as scheduled.

Mainland China

Coronary Products

PTCA Balloon YAN

Coronary DCB AcoArt Camellia®

Coronary DCB AcoArt Canna®

United States

CEDAR Endovenous Radiofrequency Ablation System

- The Cedar RFA System received FDA 510(k) clearance in October 2025.
- The Cedar RFA has completed its first U.S. clinical application, achieving positive results.

North America & Asia Pacific

- Jointly developing three peripheral intervention products with BSC for North America and Asia Pacific markets.
- The first co-developed product is expected to reach commercialization in 2027.

Key Updates on Collaboration with BSC: R&D and Manufacturing Service

TRUSTED INNOVATION
FOR LIFE

Joint R&D

Collaboration Model

Concept & Design Input

Product Development

Regulatory Approval

BSC will make milestone payments to Acotec for R&D services.

Commercialization

● Acotec ● BSC ● Both

3

Projects ongoing

- In 2025, Acotec and BSC entered into an R&D Services Agreement to co-develop three peripheral intervention products.
- It is expected that one of the co-developed products will be commercialized in 2027.

Manufacturing Services

Neuromodulation Product

- In 2025, Acotec and BSC entered into a Supply Agreement for the OEM manufacturing of a neuromodulation product.
- The first prototypes of this product successfully rolled off the production line in 2025.

03

Product Commercialization

Leveraging 30+ launched products, we offer a comprehensive multi-department treatment solution strategy, achieving a strong competitive edge through first-mover positioning and clinical recognition.

TRUSTED INNOVATION FOR LIFE

5 Core Covered Departments

32 Approved Products

30+ Countries with Overseas Approvals

Layout Strategy:

Focused on Vascular Surgery, expanding coverage and depth in key diseases. Vertically extending along "Access -> Preparation -> Treatment", and horizontally expanding across Cardiology, Neurology, Nephrology, and Oncology departments.

Vascular Surgery

Building a Complete Product Matrix Around Peripheral Arterial and Venous Diseases

Peripheral Arterial Atherosclerotic Stenosis

Access	Preparation	Treatment
• Support Catheter 1 • Microguidewire • New-gen Support Catheter	• PTA Balloon (SFA) • PTA Balloon (BTK) • Tapered PTA Balloon • Peripheral Scoring Balloon • Peripheral High-pressure Balloon	• SFA DCB 1 • BTK DCB 1 • Peripheral Sirolimus DCB .....

Arterial Aneurysm

- Peripheral Controlled Mechanically Detachable Fibered Coil
- .....

Venous Thromboembolism 1

- Aspiration System
- Intelligent Aspiration Sensing Connector
- Embolus Removal Device
- Delivery Catheter for Aspiration Catheter
- Introducer Sheath Set

Varicose Veins

- RFA System 1

Oncology

TACE

- TACE Microcatheter
- Embolization Microspheres

Forming a Complete Product Matix Around PCI, Focusing on CTO Lesions

Cardiology

PCI

Access	Preparation	Treatment
• Coronary CTO Antegrade Microcatheter • Coronary CTO Retrograde Microcatheter • Coronary Microcatheter	• Semi-compliant PTCA Balloon • Coronary CTO Recanalization Balloon • Coronary High-pressure Balloon • Coronary OTW Balloon • Coronary Knobby Balloon • Coronary IVL System	• Coronary Paclitaxel DCB • Coronary Sirolimus DCB

TAVR

- Cardiac Valve Balloon Dilation Catheter

Nephrology

AVF Stenosis

- Paclitaxel Coated High-pressure Balloon
- AV Scoring Balloon
- SFA DCB (AVF indication expansion)

Neurology

ICAS

- Intracranial PTA Balloon
- Intracranial DCB

VAO Stenosis

- Vertebral Artery DCB 1

Underdevelopment/registration/clinical trials

1 First launched in China/First domestic product approved in China

A structured product portfolio continuously delivering incremental revenue

TRUSTED INNOVATION
FOR LIFE

Mature Foundation → Secondary Growth Drivers → New Growth Engine → Global Expansion

Mature Foundation	Secondary Growth Drivers	New Growth Engine	Global Expansion
Peripheral DCBs	**Peripheral Venous Products**	**High-Potential Products**	**Overseas Selling Ramp-up**
 SFA DCB	 Peripheral Aspiration System	 Vertebral Artery DCB	 Peripheral DCBs
 BTK DCB	 RFA System	 Peripheral Coil	 RFA System
• First-mover advantage + clinical recognition build a robust moat. • Commercialization enters the mature stage, providing stable cash flow.	• Penetration of treatment modalities is rapidly increasing. • Seizing expansion opportunities with domestic first-mover advantages.	• Multiple new products have already been launched, including but not limited to Vertebral Artery DCB and Peripheral Coil, with more products expected to receive approvals, continuing to deliver diversified revenue growth.	• With the gradual expansion of the Boston Scientific collaboration—both in products and countries covered—overseas market revenue is poised to become a key incremental driver.
Launched 10Y / 5Y	**Launched 4Y / 3Y**	**Launched 1Y**	**Overseas Commercialization 1–2Y**
Mature products deliver stable cash flow	**Venous business as a strong second growth curve**	**New products driving incremental revenue**	**International expansion unlocking long-term growth potential**

We consistently enhance the Company's professional standing in the field of peripheral vascular interventional therapy through academic and market initiatives.



SFA DCB

BTK DCB

Market Deployment:

- From top-tier hospitals to primary hospitals, we have established broad, multi-level hospital coverage.

Market Strategy:

- Support the publication of post-market clinical studies to enrich the product evidence base.
- Invite overseas experts for technical exchanges and knowledge sharing to enhance domestic doctors' treatment philosophies and techniques.

VBP:

- 2025 DCB National VBP: Full product line won the bid; We expect the penetration rate of DCB products in procedures to continue rising.



Clinical Investigation

Long-term Outcomes of the AcoArt II–BTK Trial: Drug-Coated Balloon Angioplasty Compared With Uncoated Balloons for the Treatment of Infrapopliteal Artery Lesions

Guoyi Sun, MD[1*], Jie Liu, MD[1*], Xin Jia, MD[1], Jiang Xiong, MD[1], Xiaohui Ma, MD[1], Hongpeng Zhang, MD[1], and Wei Guo, MD[1]

Abstract

Purpose: Previous studies have indicated mixed short-term outcomes between drug-coated balloon (DCB) angioplasty and percutaneous transluminal angioplasty (PTA) in the treatment of infrapopliteal lesions. However, the long-term durability of DCB angioplasty remains uncertain. The objective of this study is to present the long-term outcomes of DCB angioplasty for infrapopliteal lesions in patients with critical limb ischemia (CLI). **Materials and Methods:** The AcoArt II–BTK Trial

Peripheral Aspiration System

Peripheral RFA System

Market Deployment:

- Leveraging our first-mover advantage, we have extensively penetrated lower-tier markets, addressing the urgent demand particularly in Tier 3 and 4 cities.

Market Strategy:

- Support the publication of post-market clinical studies to enrich the product evidence base.
- Conduct training sessions to enhance doctors' skills and concepts, and promote treatment modality conversion.

VBP:

- Henan Provincial VBP: Won the bid in 2023; Successfully renewed the bid in early 2025.

Original Article

Vascular

Early outcome of percutaneous mechanical thrombectomy using the AcoStream device in combination with other endovascular therapies for deep vein thrombosis in a lower extremity

Zuanbiao Yu[1*], Tiequan Yang[2*], Ming Cai[1], Songjie Hu[1], Di Wang[1], Yafang Shao[1] and Dehai Lang[1]

Abstract

Objective: To evaluate the efficacy and safety of the AcoStream device (Acotec Scientific, Beijing, China) when used in

We have solidified our advantage with a comprehensive product matrix in the peripheral line, and multiple featured products have been approved within 2025.

TRUSTED INNOVATION
FOR LIFE

2D Structure | 3D Structure

Peripheral Controlled Mechanically Detachable Fibered Coil Lavender

- Utilizes controlled mechanical detachment technology; instant detachment is achieved with a simple fold and pull, allowing for complete retrieval and repositioning to achieve precise embolization.
- Two guidewire systems (0.018", 0.035") are compatible with various microcatheters and angiographic catheters.
- Broad clinical applications, including treatment of abdominal aortic aneurysm endoleaks, intracranial aneurysms, arteriovenous malformations, and visceral aneurysm embolization.



Peripheral Hydrophilic Guidewire

- The 10 cm flexible tip segment adopts a tapered core wire design, with an outer laser-cut nickel-titanium alloy hypotube, resulting in good product performance.
- Guidewires are used to navigate and access diseased vessels, serving as the critical first step in interventional procedures and a key determinant of procedural efficiency.
- With 300,000 to 400,000 peripheral interventional procedures performed annually—and one guidewire required per procedure—the market potential is substantial.



Prepheral PTA Balloon AcoArt Iris® & Jasmin®

Prepheral PTA Balloon AcoArt Tulip®& Litos®

Prepheral Supporting Catheter Vericor®

Prepheral Tapered Balloon P-Conic®

Prepheral Scoring Balloon E-Peridge®

Prepheral High-pressure Balloon Armoni-HP®

AcoArt Verbena: Addressing Unmet Clinical Needs with Robust Efficacy to Drive Growth

TRUSTED INNOVATION
FOR LIFE

50,000
procedures/year

- Current annual vertebral artery origin stenosis (VAOS) intervention volume is approximately 50,000, growing at a rate of 15% per year.
- Vessels on the non-dominant side (2–3 mm in diameter) are often too small for stenting – DCB addresses this unmet clinical need and unlocks new market potential.

Ischemic strokes account for **70.2%** of all strokes



25%~40% of ischemic strokes occur in the posterior circulation

- Stroke is the second leading cause of death and the third leading cause of disability globally.
- According to epidemiological survey data released by the Chinese Stroke Association, **there are 3.3 million new stroke cases annually in China.** Between 25% and 40% of ischemic strokes occur in the posterior circulation, and among these, 9% to 33% involve VAO stenosis or occlusion. Therefore, among the annual new stroke cases, an estimated **150,000 to 200,000 patients present with VAOS.**
- **Treating VAO stenosis is significant for stroke prevention.**

The vertebral artery DCB has demonstrated outstanding superiority

Clinical Trial

Treatment Group
AcoArt Verbena®
DCB



Control Group
Apollo®
Stent

180 patients
1:1 allocate to the DCB group and the Stent group.

17
research centers

3-5mm
Target lesion reference vessel diameter

≥70%
Target lesion stenosis degree

Primary Study Endpoints

√ **Superior efficacy clinical trial results**

The restenosis rate at 12-month follow-up



Source: Frost & Sullivan and CIC research reports, epidemiological survey data released by the Chinese Stroke Association, and expert interviews.

With Approvals of Our Coronary Paclitaxel and Sirolimus DCBs, We Now Offer a Comprehensive Portfolio and a Strong Commercial Outlook

TRUSTED INNOVATION
FOR LIFE

A Comprehensive Product Matrix:
Featuring Access, Vessel Preparation, and Therapeutic Devices



Coronary Paclitaxel DCB
AcoArt Camellia®

Coronary Sirolimus DCB
AcoArt Canna®

In January 2026, we successfully won the bid in the national VBP

Semi-compliant PTCA Balloon
YAN

Coronary CTO Recanalization Balloon
RT-Zero®

Coronary High-Pressure PTCA Balloon
YIYAN

Coronary OTW Balloon
Jingyi

Coronary CTO Antegrade Micro-Catheter
Vericor-14®

Coronary CTO Retrograde Micro-Catheter
Vericor-RS®

Coronary Micro-Catheter
Vericor-S2®



1,600K+/Annual Procedures

A large procedural volume base + high growth rate signifies broad market potential.

Supply Chain Advantages

Supply Chain Strength Ensures Acotec's Product Quality, Cost Control, and Sustained Supply

04

R&D, Product Approvals, and Manufacturing Status

We continuously expand R&D and production capabilities in core links of the industrial chain, focusing on building an innovation capability moat

TRUSTED INNOVATION
FOR LIFE

Raw Material Processing → Precision processing of polymers/metals

Core Component Development → Micro-extrusion molding / Balloon and catheter platform

Function Realization → Drug and functional coatings, Active energy control, Microsphere synthesis.....

Product Forming → System design / Performance verification

Large-scale Production → Process consistency / Quality and supply assurance

Precision Material Processing and Component Development

.....

Enables manufacturing of balloons, catheters, metal components, and microstructures

Establishing a robust process barrier from material to product realization

Drug/Functional Coating Technologies





.....

Determines drug loading, transfer efficiency, release and retention profile

Creating performance differentiation for products

Active Energy Control Technologies

.....

Capabilities in power control, temperature monitoring, impedance feedback, and consistent energy delivery

Building technological barriers for active medical devices

The Company has established a multi-dimensional technology platform that forms a complete value chain from raw material processing to large-scale production, driving R&D efficiency, product customization capability, and supply chain resilience.

In 2025, we brought 11 new products to market, setting a record for annual product approvals.

TRUSTED INNOVATION
FOR LIFE

11 new products launched in China—a record high for annual approvals

Neurology

Vertebral DCB AcoArt Verbena®

Oncology

TACE Microcatheter V-otter

Cardiology

Coronary Sirolimus DCB AcoArt Canna®

Coronary Microcatheter Vericor-S2®

Coronary OTW Balloon Jingyi®

Vascular Surgery

Pressure-Control Thrombus Aspiration Extension Tube

Embolus Removal Device for Peripheral Thrombus Aspiration Catheter

Peripheral Scoring Balloon E-Peridge®

Peripheral High-Pressure Balloon Armoni-HP®



Peripheral Hydrophilic Guidewire



Peripheral Controlled Mechanically Detachable Fibered Coil

The BTK DCB AcoArt Litos® : Multiple clinical trial sites activated in U.S./Europe, patient enrollment ongoing

TRUSTED INNOVATION
FOR LIFE

AcoArt Litos®



The IDE application received FDA approval on Nov 29, 2023



Litos was granted designation as Breakthrough Device from FDA in 2019

- ✓ US and European sites simultaneously activated
- ✓ Patient enrollment progressing systematically
- ✓ US BTK surgery volume is 150,000/year, indicating broad application prospects for DCB

FIRST COAST CARDIOVASCULAR INSTITUTE

COLUMBIA UNIVERSITY

SOUTH CHARLOTTE GENERAL & VASCULAR SURGERY

UT Southwestern Medical Center

- We have collaborated with leading U.S. sites and PIs in peripheral vascular disease.

- Acotec BTK DCB received CE Mark in 2014 and has been in clinical use in Europe for nearly a decade. European PIs are well-versed in the product and possess extensive clinical experience.

Enrollment in progress

Dual - Base Synergistic Production Strategy: Sufficient Capacity for Growing Market Demand and OEM Business

TRUSTED INNOVATION
FOR LIFE

4+M Units/Year*

BEIJING	SHENZHEN
30,800㎡	11,543㎡

Sufficient to Meet Growing Market Demand and Potential OEM Needs

Lab/ Production Area / Office/ Clean Room

Dual Production Bases: Beijing & Shenzhen

Beijing New Facility

Shenzhen Manufacturing Facility

*Note: Maximum capacity can be achieved when production bases in Beijing and Shenzhen are fully operational with double shifts.

AGOTEC
先瑞达

TRUSTED INNOVATION
FOR LIFE

05

Q&A

AGOTEC
先瑞达

THANKS!

谢谢！

TRUSTED INNOVATION
FOR LIFE

Products and Pipeline-Full Product Portfolio (1/2)

TRUSTED INNOVATION
FOR LIFE

Department	Products and Product Candidates	Indications / Applications	Key Technologies	Phase				Upcoming Milestone
				Area	Pre-clinical Studies	Clinical Studies	Registration	
Vascular Surgery	AcoArt Orchid® & Dhalia®/Orchid Plus★ Note 1	Superficial femoral artery (SFA) and popliteal artery (PPA) disease	Drug coating technology	China	✓	✓	NMPA Approval★	/
				EU	✓	✓	CE★	/
	AcoArt Tulip®& Litos®★	Below-the-knee (BTK) artery disease	Drug coating technology	China	✓	✓	NMPA Approval★	/
				EU	✓	✓	CE★	/
				U.S.	✓	✓		
	AcoArt Iris® & Jasmin®	PTA Balloon applied in PTA procedure	Polymer materials	China	✓	✓	NMPA Approval★	/
	AcoArt Lily® & Rosmarin®	PTA Balloon applied in PTA procedure	Polymer materials	China	✓	✓	NMPA Approval★	/
	Peripheral Aspiration System (AcoStream®)▲	DVT, ALI	Aspiration platform	China	✓	Exempted from clinical trial	NMPA Approval★	/
	Radiofrequency Ablation System (AcoArt Cedar®)	Saphenous varicose veins	RF platform	China	✓	✓	NMPA Approval★	/
	Peripheral Support Catheter (Vericor®)▲	Peripheral CTO lesion	Polymer materials	China	✓		NMPA Approval★	/
				U.S.	✓		FDA Approval★	/
				Brazil	✓	Exempted from clinical trial	ANVISA Approval★	/
				Thailand	✓		TFDA Approval★	/
				Japan	✓		MHLW Approval★	/
	PTA Balloon (P-Conic®)	PTA	Polymer materials	China	✓	Exempted from clinical trial	NMPA Approval★	/
	2nd Gen Peripheral Aspiration System (2nd Generation AcoStream®)▲	DVT, ALI	Aspiration platform	China	✓		NMPA Approval★	/
				U.S.	✓	Exempted from clinical trial		2027
				EU	✓			2027
	Introducer Sheath Set (Acotrace)▲	PTA	Polymer materials	China	✓	Exempted from clinical trial	NMPA Approval★	/
	Delivery Catheter for Aspiration Catheter▲	DVT	Polymer materials	China	✓	Exempted from clinical trial	NMPA Approval★	/
	Pressure-Control Thrombus Aspiration Extension Tube▲	DVT	Aspiration platform	China	✓	Exempted from clinical trial	BMPA Approval★	/
	Embolus Removal Device for Peripheral Thrombus Aspiration Catheter	DVT	Aspiration platform	China	✓	✓	NMPA Approval★	/
	Peripheral Scoring Balloon (E-Peridge®)	PTA	Polymer materials	China	✓	✓	NMPA Approval★	/
	Peripheral High-Pressure Balloon (Armoni-HP®)	CTO	Polymer materials	China	✓	✓	NMPA Approval★	/
	Peripheral Hydrophilic Guidewire▲	PTA	Polymer materials	China	✓	Exempted from clinical trial	BMPA Approval★	/
	Peripheral Controlled Mechanically Detachable Fibered Coil (Lavender)	Embolization	Polymer materials	China	✓	✓	NMPA Approval★	/
	Lower Limb Sirolimus DCB	SFA and PPA disease	Drug coating technology	China	✓	✓		2027
	Next-Gen Peripheral Support Catheter▲	Peripheral CTO lesion	Polymer materials	China	✓	Exempted from clinical trial		2027

★Core product ☆ Indication expansion of core product ★Commercialization

▲Exempted from clinical trial requirements in accordance with the Catalogue of Medical Device Exempted from Clinical Trials (免於進行臨床試驗醫療器械目錄)) promulgated by the NMPA as amended.

Note 1: We have been continuously improving the performance of AcoArt Orchid® & Dhalia®. As advised by NMPA and as part of our business strategy, we decided not to register Orchid Plus as a separate product. Alternatively, we applied to register Orchid Plus as an upgrade version of AcoArt Orchid® & Dhalia® with improved delivery balloon catheter system, and received the revised NMPA approval for AcoArt Orchid®& Dhalia® in November 2021.

Products and Pipeline-Full Product Portfolio (2/2)

TRUSTED INNOVATION
FOR LIFE

Department	Products and Product Candidates	Indications / Applications	Key Technologies	Phase				Upcoming Milestone
				Area	Pre-clinical Studies	Clinical Studies	Registration	
Cardiology	Semi-compliant PTCA Balloon (YAN) ▲	PTCA	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	/
	Coronary CTO Recanalization Balloon (RT-Zero®)▲	Coronary CTO	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	/
	Coronary CTO Antegrade Micro-Catheter (Vericor-14®) ▲	Coronary CTO	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	/
				Japan			MHLW Approval★	/
				Thailand			TFDA Approval★	/
	Coronary Retrograde Micro-Catheter (Vericor-RS®) ▲	Coronary CTO	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	
	Coronary High-Pressure Balloon (YIYAN) ▲	PTCA	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	
	Coronary Paclitaxel DCB (AcoArt Camellia®)	Coronary small vessel diseases	Drug coating technology	China			NMPA Approval★	
	Cardiac Valve Balloon (RunFlow®)	TAVR	Polymer materials	China			NMPA Approval★	
	Coronary Micro-Catheter (Vericor-S2®)▲	PCI	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	/
	Coronary Sirolimus DCB (AcoArt Canna®)	Bifurcation lesions	Drug coating technology	China			NMPA Approval★	/
	Coronary OTW Balloon Dilatation Catheter (Jingyi)	PTCA	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	/
	Coronary IVL System	Coronary lesion calcium	Polymer materials	China				2027
	Coronary Knobby Balloon Dilatation Catheter	PTCA	Polymer materials	China				2027
Nephrology	AcoArt Orchid®& Dhalia®/Orchid Plus☆(DCB)	Arteriovenous fistula stenosis	Drug coating technology	China			NMPA Approval★	/
	Paclitaxel Coated High-pressure Balloon (ACOART AVENS®)	AVF PTA procedure	Drug coating technology	China			NMPA Approval★	/
	AV Scoring Balloon (Peridge®)	AVF PTA procedure	Polymer materials	China			NMPA Approval★	/
Neurology	Intracranial PTA Balloon (NEO-Skater®)▲	Intracranial PTA procedure	Polymer materials	China		Exempted from clinical trial	NMPA Approval★	/
	AcoArt Verbena® (DCB)	Vertebral atherosclerotic stenosis	Drug coating technology	China			NMPA Approval★	/
	Intracranial DCB (AcoArt Daisy®)	Intracranial atherosclerotic stenosis	Drug coating technology	China				2027
Oncology	Microcatheter (V-otter)	TACE	Polymer materials	China			NMPA Approval★	/
	Embolization Microspheres	TACE	Microsphere Synthesis Technology	China				2027

★Core product ☆ Indication expansion of core product ★Commercialization

▲ Exempted from clinical trial requirements in accordance with the Catalogue of Medical Device Exempted from Clinical Trials (《免於進行臨床試驗醫療器械目錄》) promulgated by the NMPA, as amended.